This review summarises existing evidence describing PSA reference ranges for TWNBPP receiving GAHT, with the aim of providing guidance for clinicians for when to refer symptomatic TWNBPP for further prostate cancer investigations and for screening advice for TWNBPP who seek screening due to increased prostate cancer risk. The gene discussed is KLK3; the disease is prostate carcinoma.